MAIA Biotechnology Says Enrollment In Phase 3 THIO-104 Lung Cancer Trial Of Ateganosine Reaches 65, Targets Over 100 By Year-End
Share
Why It Matters
MAIA is testing a new lung cancer medicine on more patients. When a company enrolls more people in a test, it shows progress toward proving the medicine works.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.